Abbvie Expects $3B In Hepatitis C Drug Sales And 40% Of Insured Customers

Abbvie, the maker of one of the costly hepatitis C pills captivating Wall Street and frustrating those who pick up the tab for health care costs, says its sales of its treatment will generate more than $3 billion in annual sales in 2015. AbbVie’s Vierkira Pak was approved last month and like rival treatments sold by Gilead has faced resistance among private health insurers and government health programs like Medicaid plans for poor Americans.

[button title=”read more” link=”http://www.forbes.com/sites/brucejapsen/2015/01/30/abbvie-expects-3b-in-hepatitis-c-drug-sales-and-40-of-insured-customers/” target=”_blank” size=”” color=”” class=””]